Low Serum Glutathione Peroxidase Activity Is Associated with Increased Cardiovascular Mortality in Individuals with Low HDLc’s by Buijsse, Brian et al.
Low Serum Glutathione Peroxidase Activity Is Associated
with Increased Cardiovascular Mortality in Individuals
with Low HDLc’s
Brian Buijsse
1,2, Duk-Hee Lee
1,6, Lyn Steffen
1, Richard R. Erickson
3, Russell V. Luepker
1,
David R. Jacobs, Jr.
1,7, Jordan L. Holtzman
3,4,5*
1Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America, 2Department of
Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, 3Department of Pharmacology, University of Minnesota, Minneapolis,
Minnesota, United States of America, 4Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America, 5Division of Environmental
Health Sciences, University of Minnesota, Minneapolis, Minnesota, United States of America, 6Division of Preventive Medicine, School of Medicine, Kyungpook National
University, Jung-gu, Daegu, South Korea, 7Department of Nutrition, University of Oslo, Oslo, Norway
Abstract
Background: Since oxidized LDL is thought to initiate atherosclerosis and the serum glutathione peroxidase (GPx3) reduces
oxidized lipids, we investigated whether high GPx3 activity reduces cardiovascular disease (CVD) mortality.
Methods:Wedetermined GPx3instored samples fromthe MinnesotaHeart Surveyof 130participants whoafter5to 12years
offollow-uphaddiedofCVDand240controls.Participantswere26to85yearsoldandpredominantlywhite.Inanestedcase-
control, study we performed logistic regressions to calculate odds ratios (OR) adjusted for age, sex, baseline year, body mass
index,smoking,alcoholintake,physicalactivity,totalandHDLcholesterols,systolicbloodpressure,serumglucoseandgamma
glutamyltransferase (GTT) activity. The referent was the quartile with the highest GPx3 activity (quartile 4).
Results: OR’s for CVD mortality for increasing quartiles of GPx3 were 2.37, 2.14, 1.83 and 1.00 (P for trend 0.02). This inverse
correlation was confined to those with HDLc’s below the median (P for interaction, 0.006). The OR’s for increasing quartiles
of GPx3 in this group were 6.08, 5.00, 3.64 and 1.00 (P for trend, 0.002).
Conclusions: Individuals with both low HDLc and GPx3 activity are at markedly increased risk for death from CVD.
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Introduction
It is widely held that oxidative stress is a major factor in the
vascular injury that leads to atherosclerosis and CVD [1] In spite
of the failure of dietary antioxidants to decrease CVD incidence
[2], there is still a significant body of evidence suggesting that
oxidative injury has a major role in the initiation of atherosclerosis
[3]. These findings include the observation that oxidized serum
lipid levels are higher in patients with CVD than in controls [3,4–
6]. Similarly, Salonen et al. [7] have reported that patients have
antibodies to oxidized lipids suggesting that they have a greater
exposure to these toxic products than do controls. If oxidized
lipoproteins are a major factor in the development of atheroscle-
rosis, then endogenous systems that reduce the levels of these toxic
products may be important in the prevention of CVD.
The glutathione peroxidases (GPx) are a family of enzymes
which reduce oxidized lipids to their nontoxic metabolites and
may thereby decrease vascular injury [3]. The two major forms
are GPx1 and GPx3. GPx1 is found solely in the cytosol and
mitochondria, whereas GPx3 is only present in HDL particles
[3,8]. They reduce oxidative stress by catalyzing the glutathione
dependent reduction of lipid hydroperoxides to their correspond-
ing alcohols and hydrogen peroxide to water [3].
Previous studies have suggested that low levels of both GPx1
and GPx3 are associated with the development of vascular disease.
For example, in the Athero Gene study of patients with a history of
CVD, those with low erythrocyte GPx1 activities had an increased
incident of recurrent events [9,10]. Similarly, in a case-control
study, Voetsch et al. [11] found that several single nucleotide
polymorphisms (SNP’s) in the GPx3 gene promoter region, which
decreased the expression of this enzyme [12], were associated with
an increased incidence of ischemic stroke before the age of 45. Yet,
no prospective, population based studies on the association
between GPx3 activity and CVD have been reported.
We have performed a nested, case-control analysis of stored
serum samples from the Minnesota Heart Survey to determine
whether high GPx3 activity may reduce CVD mortality.
Consistent with its presumed role in reducing oxidative injury,
we hypothesized that a higher activity would be associated with a
lower incidence of CVD. In a subgroup analysis, we anticipated
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38901that there may be a greater inverse correlation between outcomes
in those with low and high HDLc’s, since those with low levels
are likely to need additional antioxidant activity in order to
prevent CVD.
Methods
Subject Selection
The subjects were participants in the Minnesota Heart Survey.
Methods of this study have been previously published [13–15].
Briefly, it was initiated in 1980 as an ongoing population-based
surveillance survey on the trends of risk factors for CVD in
residents of the seven counties of the Minneapolis-St. Paul
metropolitan area. A two-stage, self-weighting cluster design was
used to randomly select households. Within each household, one
individual was randomly selected to participate in the survey
except for the 1980–1981, 1995–1997, and 2000–2002 surveys in
which all age-eligible household members were invited to
participate [16]. Since the subjects were not seen after their initial
evaluation, the follow-up mortality was determined by matching
subjects with the Minnesota death certificates filed on or before
December 31, 2002. Written consents were obtained from all
study participants. The consents and data collection procedures
for each survey were approved by the University of Minnesota
Research Subjects’ Protection Programs Institutional Review
Board.
For this study, we used data and stored serum samples from
the 1990–1992 and 1995–1997 surveys. We identified 173 CVD
deaths (International Classification of Diseases ninth revision
codes 390–459 or tenth revision codes I00–I99) and two age
and sex matched controls per case (n=346). Serums were
available from 137 of the participants who had died and 250
controls. Three controls died during follow-up from causes other
than CVD. The subjects ranged in age from 26 to 85 years.
Missing blood samples occurred more frequently in the 1995–
1997 survey than in the earlier collection period. There were 96
cases and 198 controls from the 1990–1992 survey and 41 cases
and 51 controls from the 1995–1997 survey. Complete covariate
data were available in 130 cases (95 in 1990–1992 and 35 in
1995–1997) and 240 controls (197 in 1990–1992 and 43 in
1995–1997). Findings were essentially unaffected if the 16
missing covariate values were imputed from the participants’
sex, age, body mass index (BMI), and diabetes status, but we
report our findings only from those with a complete data set
because 12 of the missing values were for their HDLc levels, a
variable which we had postulated could play a role in our
analysis.
Table 1. Baseline characteristics of the study population by case-control status, in the Minnesota Heart Survey.*
Characteristic Cases (N=130) Controls (N=240) P
{
Males – % (no.) 57.7 (75) 56.7 (136) 0.85
Age – yr 69.2611.9 67.9612.2 0.33
BMI – kg/m
2 27.865.1 27.364.3 0.16
Current smoker – % (no.) 20.8 (27) 8.3 (20) 0.0006
Alcohol – drinks per week 5.6612.8 3.466.8 0.07
Physical activity – MET-hr/day 8.5612.7 7.8610.7 0.60
Serum cholesterol – mg/dl
Total 220643 216638 0.43
HDLc 41614 45615 0.03
Lipid-lowering medication – % (no.) 13.8 (18) 6.7 (16) 0.02
Hypercholesterolemia – % (no.)
I 41.5 (54) 32.1 (77) 0.06
Blood pressure – mmHg
Systolic 135.9618.5 130.1618.9 0.005
Diastolic 75.7612.7 74.6610.6 0.37
Antihypertensive use – % (no.) 40.8 (53) 25.4 (61) 0.002
Hypertension - % (no.)
1 66.9 (87) 43.8 (105) ,0.0001
Self-reported diabetes – % (no.) 19.2 (25) 7.5 (18) 0.0008
Aspirin use – % (no.) 39.2 (51) 35.0 (84) 0.52
Enyme activities in serum
GPx3– U/ml, mean 6 SE
" 0.3460.01 0.3760.01 0.02
GGT – U/l 43.3669.7 25.9618.3 0.006
Non-fasting serum glucose – mg/dl 130662 109636 0.0008
Urea nitrogen – mg/dl 19.769.2 18.164.9 0.07
*Value are the means6SD, unless otherwise indicated.
{Based on 2-sample t-test, Mann-Whitney U test, or Chi-square test.
1Defined as a blood pressure of $140/90 mm Hg or the use of antihypertensive medication.
IDefined as a serum total cholesterol .200 mg/dl.
"Means for the activity of GPx3 (standard error) were adjusted for baseline year in a covariance analysis.
doi:10.1371/journal.pone.0038901.t001
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Subjects’ heights were measured in their stocking feet with a
wooden triangle by a rigid ruler attached to the wall. Weight was
measured with a beam balance without the subjects wearing either
a coat or shoes. The BMI was calculated as the weight in kg
divided by the square of the height in m.
Systolic and fifth phase diastolic blood pressures were measured
with a random zero sphygmomanometer (Hawksley, West Sussex,
United Kingdom) by trained technicians according to a standard
procedure [16]. The recorded blood pressures were the average of
two measurements taken 1 minute apart.
Information on age, sex, leisure-time physical activity, smoking,
and alcohol consumption was obtained by interviewer-adminis-
tered questionnaires. For leisure-time physical activity, questions
were asked about the intensity, duration, and frequency of
exercise. Using these data we derived a physical activity score in
MET-hr/day [17].
Laboratory Serum Assays
Blood was drawn from non-fasting subjects according to
standardized protocols that differed in one important respect
between the 1990–1992 and 1995–1997 surveys. In the 1990–
1992 survey serum samples were refrigerated at 4uC for up to
several days before freezing while in the 1995–1997 survey they
were frozen at 270uC within 24 hours. Upon receipt in the
laboratory, all serum samples were stored at 270uC. Serum was
used for all laboratory analyses.
Total serum cholesterol was determined with an AutoAnalyzer
II (Technicon Corporation) by a nonenzymatic method in 1990–
1992 and an enzymatic method thereafter. HDLc was determined
by an enzymatic method after heparin and Mn2+ (1990–1992)
[18] or magnesium dextran sulfate (1995–1997) precipitation of
non-HDLc [19]. Glucose, urea nitrogen, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT) and GGT were
determined in a Vitros 950 multi-channel analyzer (Ortho Clinical
Diagnostics, Raritan, NJ) by the manufacturer’s standard thin-
layer reflectance spectrophotometric methods. Average analytical
coefficient of variation (CV) for these assays at the high end of the
normal range were less than 3%.
GPx3 activity was determined by a modified kinetic assay as
previously described [8]. Briefly, serum samples were aliquoted in
quadruplicate into 96 well microtiter plates. Glutathione and
glutathione reductase were added. After warming to 37uC NADPH
andt-butylhydroperoxide,wereadded.Thedecreaseinabsorbance
at 340 nm was determined kinetically in a microtiter plate reader
(FLUOstar, BMG, Offenberg, Germany). The CV’s were 5%
within each plate. We presumed that we were determining only the
GPx3 activity since previous studies have reported that it was the
Table 2. Cross-sectional relation between GPx3 activity and characteristics at baseline: the Minnesota Heart Survey.*
Characteristic Baseline Quartiles of serum GPx3 activity
{
P trend
{
Q1 Q2 Q3 Q4
No. of controls 60 61 60 59
Males – % (no.) 60.0 (36) 55.7 (34) 61.7 (37) 49.2 (29) 0.81
Age – yr 66.6611.3 68.4613.5 68.1612.8 68.5611.1 0.52
BMI – kg/m
2 27.764.4 26.864.6 26.963.4 27.864.8 0.46
Current smoker – % (no.) 8.3 (5) 6.6 (4) 11.7 (7) 8.5 (5) 0.86
Alcohol – drinks per week 2.566.1 3.265.1 4.769.4 3.165.6 0.33
Physical activity – MET-hr/day 9.1612.2 7.069.8 6.869.5 8.2611.4 0.63
Blood pressure – mmHg
Systolic 133.9620.7 130.6619.4 128.2616.9 127.8618.4 0.26
Diastolic 75.3610.0 75.4611.6 74.069.6 73.5611.3 0.71
Antihypertensive use – % (no.) 30.0 (18) 24.6 (15) 20.0 (12) 27.1 (16) 0.64
Hypertension - % (no.)
1 51.7 (31) 50.8 (31) 33.3 (20) 39.0 (23) 0.11
Serum cholesterol – mg/dl
Total 214636 219634 213643 219639 0.73
HDLc 43614 50614 45614 42615 0.03
Lipid-lowering medication – % (no.) 10.0 (6) 0.0 (0) 11.7 (7) 5.1 (3) 0.04
Hypercholesterolemia – % (no.)
I 28.3 (17) 31.1 (19) 35.0 (21) 33.9 (20) 0.89
Self-reported diabetes – % (no.) 10.0 (6) 4.9 (3) 6.7 (4) 8.5 (5) 0.74
Aspirin use – % (no.) 33.3 (20) 36.1 (22) 23.3 (14) 42.4 (25) 0.17
GGT – U/l 28.1621.6 26.2617.2 23.6614.0 25.7619.8 0.61
Non-fasting serum glucose – mg/dl 115655 110630 105624 108626 0.47
Urea nitrogen – mg/dl 17.463.9 17.764.4 17.863.8 19.666.8 0.05
*The values are the means6SD, unless otherwise indicated.
{Shown are the year-specific quartiles of GPx3 activity, based on the distribution in controls. Ranges of GPx3 activity in U/ml for increasing quartiles were 0.09–0.23,
0.24–0.30, 0.31–0.42, and 0.43–0.76 in 1990–1992, and 0.17–0.35, 0.36–0.47, 0.48–0.56, and 0.57–1.03 in 1995–1997.
{Based on modeling quartiles of GPx3 activity as a continuous variable.
1Defined as a blood pressure of $140/90 mm Hg or the use of antihypertensive medication.
IDefined as a serum total cholesterol .200 mg/dl.
doi:10.1371/journal.pone.0038901.t002
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in the 1990–1992 samples than those from 1995–1997(see Results).
The assay was consistent, in that the same survey differences
occurred on the single assay plate that contained samples from both
surveys (mean (SD) GPx3 activity 0.36 (0.13) U/ml in 13 samples
from 1990–1992 compared with 0.76 (0.07) U/ml in eight samples
from 1995–1997).
Data Analysis
Case-control differences in GPx3 activity were similar within
participants in the 1990–1992 and the 1995–1997 surveys, hence
the primary findings were based on analyses of pooled data from
the two surveys. However, given the difference in GPx3 activity
between the two and the differences in the number of case-control
blood samples that were available between the two collection
periods, we also present survey specific data to demonstrate that
our findings were consistent between surveys. In the pooled
analyses, we adjusted for survey period and used baseline year-
specific quartiles based on the distribution in controls in assessing
the association between GPx3 activity and CVD mortality. Since
our initial hypothesis was that high levels of GPx3 are protective,
we elected to take the highest quartile as the referent. We report
the odds ratios (OR) for CVD mortality calculated by logistic
regression models. All analyses were adjusted for age, sex, and
baseline year (model 1). In multivariable analyses, we first included
the BMI, cigarette smoking, physical activity, and alcohol intake
(model 2). This model was then extended by adding the values for
the total HDLc’s, systolic blood pressure, non-fasting serum
glucose levels and GGT activities (model 3). Trends across
quartiles of GPx3 activity were assessed by modeling the GPx3
activity as a continuous variable. Stratified analyses for the HDLc
were conducted to determine whether the association between
GPx3 activity and CVD mortality differed between those above
and below the sex-specific median values for the HDLc’s. This
stratification was based on the hypothesis that both HDL and
GPx3 may prevent vascular injury by removing oxidized lipids
from the serum. If such is the case, then they could serve as
complimentary antioxidant systems. The sex-specific median
values for the HDLc were similar for the 1990–1992 and 1995–
1997 surveys. A product term of GPx3 (quartiles) and HDLc
(continuous) was entered into the multivariable model to assess the
statistical significance of this interaction. All analyses were
conducted with the SAS version 9.1 (SAS Institute Inc., Cary,
NC).
Table 3. Odds ratios (ORs) and 95% confidence intervals (CIs) of cardiovascular mortality by serum GPx 3 activity.
Baseline Quartiles of serum GPx-3 activity *
Q1 Q2 Q3 Q4
Regression
coefficient (SE)
{ P
All subjects
No. of cases/controls 43/59 35/60 32/61 20/60
Odds ratio (95% CI)
Model 1
1 2.30 (1.20–4.94) 1.81 (0.93–3.50) 1.60 (0.82–3.11) Referent 20.30 (0.14) 0.03
Model 2
I 2.26 (1.16–4.43) 1.78 (0.90–3.54) 1.59 (0.79–3.18) Referent 20.28 (0.14) 0.05
Model 3
" 2.37 (1.16–4.86) 2.14 (1.03–4.42) 1.83 (0.87–3.84) Referent 20.30 (0.15) 0.04
Low HDLcl
**
No. of cases/controls 35/35 20/26 15/20 9/33
Odds ratio (95% CI)
Model 1
1 3.79 (1.57–9.14) 2.80 (1.08–7.22) 2.73 (1.00–7.43) Referent 20.52 (0.19) 0.005
Model 2
I 4.33 (1.72–10.9) 3.39 (1.25–9.19) 3.05 (1.06–8.79) Referent 20.57 (0.20) 0.004
Model 3
" 6.08 (2.12–17.4) 5.00 (1.63–15.3) 3.64 (1.10–12.0) Referent 20.68 (0.22) 0.002
High HDLc
**
No. of cases/controls 8/24 15/34 17/41 11/27
Odds ratio (95% CI)
Model 1
1 0.87 (0.29–2.56) 1.11 (0.43–2.86) 0.99 (0.39–2.50) Referent 0.09 (0.22) 0.67
Model 2
I 0.78 (0.24–2.56) 1.02 (0.36–2.94) 1.04 (0.37–2.89) Referent 0.15 (0.23) 0.53
Model 3
" 0.82 (0.23–2.89) 1.13 (0.38–3.36) 1.10 (0.39–3.13) Referent 0.12 (0.24) 0.62
*Shown are the year-specific quartiles of GPx3 activity, based on the distribution in controls. Ranges of GPx3 activity in U/ml for increasing quartiles were 0.09–0.23,
0.24–0.30, 0.31–0.42, and 0.43–0.76 in 1990–1992, and 0.17–0.35, 0.36–0.47, 0.48–0.56, and 0.57–1.03 in 1995–1997. The highest quartile of GPx3 activity (quartile 4) was
used as the referent.
{Shown are regression coefficients (standard errors) predicting the case-control logit per standard-deviation (0.16 U/ml) increase of GPx3 activity.
1Adjusted for matching factors age (continuous) and sex, and baseline year.
IAdjusted as in model 1, but with additional adjustment for body mass index (continuous), current cigarette smoking, alcohol use (dummy variables in drinks per week:
1–6, 7–14, .14), and physical activity (continuous).
"Adjusted as in model 2, but with additional adjustment for total cholesterol (continuous), HDLc (continuous), systolic blood pressure (continuous), non-fasting glucose
(continuous), and GGT (continuous). In stratified analysis, adjustment for HDLc was omitted.
**Low HDLc was defined as lower than the median serum value of 38 mg/dl for men and 48 mg/dl for women, high serum HDLc as greater or equal to 38 mg/dl in men
and 48 mg/dl in women.
doi:10.1371/journal.pone.0038901.t003
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Baseline Characteristics
Ofthe130CVDdeathsincludedinouranalyses,66(51%)haddied
ofcoronaryheartdisease,25(19%)ofatheroscleroticstroke,22(17%)
of other atherosclerotic CVD and 17 (13%) of non-atherosclerotic
CVD. 95% of the cases and 97% of the controls were of white race.
Cases were more likely to have smoked, had higher average systolic
blood pressures, non-fasting serum glucoses and serum GGT’s [22]
and lower average HDLc’s than did the controls (Table 1).
Furthermore, they were more likely to have used medications for
hypertensionandhyperlipidemia,andself-reportedhavingdiabetes
mellitus.Thesedifferencesweremutuallyindependent,apartfroma
higher prevalence of diabetes in the cases, which lost statistical
significance after regression adjustment for the other risk factors for
CVD.TheGPx3activitieswerelowerinthecasesthaninthecontrols,
but varied between surveys. The mean (SD) activity for samples
collectedin1990–1992was0.32(0.12)U/ml,whilethosecollectedin
1995–1997had a meanvalue of0.51(0.19)U/ml. The case-control
differencesweregenerallysimilarbetweenthetwosurveys.TheAST
andALTactivitieswerealsohigherinbothcasesandcontrolsinthe
samples from 1995–1997 than those from 1990–1992. The survey
differences for these three activities were most likely due to the
differencesinthehandlingoftheserumsamples.TheGGTactivities
and serum lipids, glucose, and urea nitrogen concentrations were
comparable between the two surveys (data not shown). Among
controls,theGPx3activitywasunrelatedorinconsistentlyrelatedto
thecovariatesstudied(Table2)andtherewerenonotabledifferences
in GPx3 associations with covariates between the 1990–1992 and
1995–1997 surveys (data not shown).
Serum GPx3 Activity and Cardiovascular Mortality
The GPx3 activities were inversely and dose-dependently
correlated with CVD mortality after controlling for the matching
factors of age, sex, and baseline year (Table 3). Additional
adjustment for conventional cardiovascular risk factors and GGT
activity had little effect on the strength of this association. The
regression coefficients predicting the case-control logit per
standard deviation of GPx3 were consistently negative between
the two survey periods: 20.48 (p=0.02) in 1990–1992 and 20.10
(p=0.70) in 1995–1997.
In a subgroup analysis, the association between GPx3 and CVD
mortality was restricted to participants with below sex-specific
median HDLc (cut points were 38 mg/dl in men and 48 mg/dl in
women). There was no correlation between the GPx3 activity and
CVD mortality in participants with higher HDLc’s (P for
interaction, 0.006). For those with low HDLc’s, the multivariable
adjusted regression coefficients predicting the case-control logit per
standard deviation of GPx3 were consistently negative between
survey years: 20.67 (p=0.01) in 1990–1992 and 20.62 (p=0.10)
in 1995–1997, compared to the values for those at or above the
median HDLc’s (20.08 in 1990–1992 and 0.43 in 1995–1997.)
Neither of these values was significantly different from zero.
When we examined the joint association of GPx3 activity and
HDLc with CVD mortality, we took the highest GPx3 quartile
(quartile 4) and the below median HDLc concentration as the
single referent. Compared with this referent, the multivariable-
adjusted risk for CVD mortality increased as the GPx3 activities
decreased (Figure 1). Compared to those in the highest GPx3
quartile, the OR’s for the first, second, and third quartiles in this
group were 6.08, 5.00, and 3.64, respectively (P for trend, 0.002).
In contrast, in those at or above the median HDLc concentration,
the risk for CVD mortality across quartiles of GPx3 was constant
and similar to the risk seen in those with low HDLc and high
GPx3 activity.
After excluding cases who had died of non-atherosclerotic
CVDs (n=13), the association between GPx3 activity and
cardiovascular mortality in those with below median HDLc’s
remained essentially the same compared to those in the lowest
GPx3 quartile. The multivariable-adjusted OR’s in the first,
second, and third quartile were 5.13, 4.23, and 2.96, respectively
(P for trend, 0.003). Additional adjustments for the use of aspirin,
medication for hyperlipidemia or hypertension, or the presence of
diabetes mellitus did not affect these estimates. The association
between GPx3 activity and CVD mortality was also not
significantly different between smokers and non-smokers (P for
interaction, 0.52), or when corrected for alcohol intake (P for
interaction, 0.08) or age (P for interaction, 0.14).
Discussion
In this nested, case-control, prospective study, the serum GPx3
activity was inversely and linearly correlated with CVD mortality,
including coronary heart disease, other atherosclerotic disease and
stroke. A subgroup analysis indicated that this association between
low GPx3 activity and CVD mortality was only seen in subjects
with low HDLc and was independent of conventional risk factors
for CVD. We feel that these observations are consistent with the
currently accepted role of oxidative injury in the development of
atherosclerosis.
It is generally thought that oxidized plasma lipids initiate and
promote atherosclerosis [1]. It would therefore be expected that
any system, such as the GPx’s, which lower oxidized lipid levels
should be protective. Hence, it is not surprising that a high serum
GPx3 activity appears to prevent CVD mortality since it is the
Figure 1. The Inverse Correlation between the GPx3 Activity by
Quartile and the OR for Cardiovascular Disease Mortality in
Individuals with High HDLc and Low HDLc. The trend in the odds
ratios for CVD mortality versus the GPx3 activity as estimated by model
3 (see Methods) from the lowest quartile of GPx3 activity (quartile 1) to
the highest (quartile 4) for individuals with sex specific HDLc at or
above the median HDLc (38 mg% for males; 48 mg% for females) and
below the sex specific HDLc. The referent is quartile 4. * P,0.05 as
compared to the reference.
doi:10.1371/journal.pone.0038901.g001
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population based studies have been published on the role of GPx3
in the prevention of CVD, a few studies have suggested that it may
have a protective role [23]. For example, one study found that
homocysteine decreased the concentration of nitric oxide through
inhibition of GPx1 [24]. Similarly, Porter et al. [25] and Dogru-
Abbasoglu et al. [26] reported that in two small cross-sectional
studies, patients with CVD had lower plasma, platelet, and
erythrocyte GPx activities than did controls. Since these were not
prospective studies, there may have been confounding factors
leading to their findings, including that the GPx3 activities may
have declined as a result of the disease process rather than being its
cause. Our study circumvented this problem, since our samples
were collected before the subjects had known CVD.
Others have also highlighted the importance of glutatiione
pathwaysinthepreventionofvascularinjury.Forexample,Voetsch
etal.[11]reportedthatthepresenceofseveralSNP’sintheGPx3gene
promoterregionwhichdecreaseditsactivity,wereassociatedwithan
increasedriskforprematureischemicstrokes[12].Finally,inacase-
control study Morrison et al. [27] found that the serum glutathiione
concentrationsintheadolescentsonsofmenwithahistoryofarecent
myocardialinfarctionweresignificantlylowerthanthoseobservedin
the serum ofsonsof age-matched controls.
In subjects with low HDLc we found that a low GPx3 activity
was associated with OR’s which would suggest that this
combination may be a major risk factor for CVD. In fact those
with this combination appear to be at a greater risk for CVD
mortality than that attributed to moderate hypertension, diabetes
mellitus, smoking a pack of cigarettes per day or a LDL in the
200 mg/dL range, where the OR’s are usually considered to be
around 2–4 [28].
Our study has a number of major limitations. The most
important is that the subjects were not seen in follow up after their
initial visit. Hence we are unable to determine what effect the low
HDL and GPx3 activity may have had on nonfatal CVD events.
Similarly, we had no follow up on other possible effects of this
combination, such as the intercurrent incidence of new onset
diabetes, hypertension and hyperlipidemia. Furthermore, the
question of whether the patients had diabetes was not verified in
our laboratory. Finally, since the enzyme assays were run after a
long storage time at –80
o C, we cannot be certain that there had
not been a loss of activity.
In conclusion, we have found in a nested, case-control study
that the GPx3 activity is negatively correlated with CVD
mortality. This association appears to be limited to individuals
with a low HDLc.
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